Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
With only 2652 shares traded so far, I see the fakers are truly loading da boat!
The circus is back in town and the clowns are peddling their snake oil
LOL ROFL PIMPL!
"Having had confirmatory studies supporting the increase in NR2F6 gene expression, we now want to see what is happening when these cells are put in a relatively natural environment in the presence of activated immune cells, " says Dr. David Koos, Chairman and CEO of the company. "If these cells do indeed suppress these immune cells, then we will have in hand a potentially extremely valuable approach to suppressing autoimmunity."
In other words, the company doesn't know what it is doing as shown with the failed result of the original test when looking at the original hypothesis of the Nerf receptor. The company is spinning the results. The new results won't lead the company anywhere because no legit pharma will want to deal with a known shyster CEO by the name David Dooshbag Koos.
Yeah, ready to go NOWHERE.
The PND just won't work here. Everyone knows this is trash and run by a konman who does deals with convicted criminals (see CEO of Oncology Pharma)
The Company is now preparing a series of in vitro experiments to determine if these DuraCAR cells are indeed immunosuppressive, rather than possessing anti-tumor activity as originally envisioned.
$RGBP has filed patents on shRNA that is designed to inhibit NR2F6 expression in CAR-T Cells and make these CAR-T cells have long-term, durable effectiveness.
👉Currently in pre-clinical development
👉We expect that inhibition of this checkpoint protects CAR-T cells from exhaustion, a common problem of existing CAR-T cell therapies
👉Blocking NR2F6 in CAR-T cells should also make these cells more effective at killing solid tumors.
Great news - The Company is now preparing a series of in vitro experiments to determine if these DuraCAR cells are indeed immunosuppressive, rather than possessing anti-tumor activity as originally envisioned.
"Having had confirmatory studies supporting the increase in NR2F6 gene expression, we now want to see what is happening when these cells are put in a relatively natural environment in the presence of activated immune cells, " says Dr. David Koos, Chairman and CEO of the company. "If these cells do indeed suppress these immune cells, then we will have in hand a potentially extremely valuable approach to suppressing autoimmunity."
Future experiments will then be designed to optimize these cells for protecting against major autoimmune disorders such as type 1 diabetes, colitis and arthritis. $RGBP
$RGBP Regen BioPharma, Inc. CEO Outlines Future Steps in CAR T Program
https://www.prnewswire.com/news-releases/regen-biopharma-inc-ceo-outlines-future-steps-in-car-t-program-301986597.html
SAN DIEGO, Nov. 14, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) has previously discussed initiation of its DuraCAR CAR T-cell therapeutic (https://www.prnewswire.com/news-releases/regen-biopharma-inc--begins-experiments-validating-its-proprietary-car-t-cell-therapy-301623585.html). This program is designed to create chimeric antigen T-cells that silence the gene for NR2F6. As part of the development of this program, it was discovered that NR2F6 mRNA was greatly increased, thus identifying new, unexpected and potentially extremely useful findings in developing cell therapy treatments for autoimmune disorders https://www.prnewswire.com/news-releases/studies-on-regen-biopharma-incs-duracar-indicate-potential-suppression-of-autoimmunity-company-retains-contract-research-organization-to-conduct-additional-confirmatory-studies-301931365.html.
The Company is now preparing a series of in vitro experiments to determine if these DuraCAR cells are indeed immunosuppressive, rather than possessing anti-tumor activity as originally envisioned.
"Having had confirmatory studies supporting the increase in NR2F6 gene expression, we now want to see what is happening when these cells are put in a relatively natural environment in the presence of activated immune cells, " says Dr. David Koos, Chairman and CEO of the company. "If these cells do indeed suppress these immune cells, then we will have in hand a potentially extremely valuable approach to suppressing autoimmunity."
Future experiments will then be designed to optimize these cells for protecting against major autoimmune disorders such as type 1 diabetes, colitis and arthritis.
$RGBP News Out - Regen BioPharma, Inc. CEO Outlines Future Steps in CAR T Program
SAN DIEGO, Nov. 14, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) has previously discussed initiation of its DuraCAR CAR T-cell therapeutic (https://www.prnewswire.com/news-releases/regen-biopharma-inc--begins-experiments-validating-its-proprietary-car-t-cell-therapy-301623585.html). This program is designed to create chimeric antigen T-cells that silence the gene for NR2F6. As part of the development of this program, it was discovered that NR2F6 mRNA was greatly increased, thus identifying new, unexpected and potentially extremely useful findings in developing cell therapy treatments for autoimmune disorders https://www.prnewswire.com/news-releases/studies-on-regen-biopharma-incs-duracar-indicate-potential-suppression-of-autoimmunity-company-retains-contract-research-organization-to-conduct-additional-confirmatory-studies-301931365.html.
https://finance.yahoo.com/news/regen-biopharma-inc-ceo-outlines-140000342.html
Real smart to upvote your own RGBP post. That gives me the confidence that what you post is the real deal and that I can believe what you are pushing!
LOL
ROFL PIMPL
LOL @ SMART MONEY!!! Geez, where have we heard that phrase posted before? Oh, when the pump and dump is happening!
LOL
ROFL
PIMPL!!!
As a wise green goblin once said, "THE FARCE IS WITH YOU!"
Smart money loading shares here $RGBP
RGBP Bullish chart, Bounce squeeze in my idea.
Nice find on onph , that's crazy ! Glad he got busted
How much are you being compensated to promote this fraudulent security?
If::::for some reason this drops back down to sub penny price or pennies. I probably would jump back in with some shares most likely.
RGBP Breakout soon MA200 imo https://schrts.co/mhqjQyhq
The FARCE is definitely with those when it comes to the blind pumping of this fraud of a company being run by a fraud CEO. What is Koos' relationship with the criminal CEO of ONPH. Remember, Koos signed a deal with sketchy ONPH. What did Koos know and when did he know it?
https://www.justice.gov/usao-ma/pr/former-stockbroker-pleads-guilty-penny-stock-securities-fraud-scheme
Let's not forget that the "confirmation" study was to confirm the results from the first study that went COUNTER to what they thought they were going to find. This tells us that the company didn't understand what they are doing initially, hence the totally opposite results (granted this is common in science) and that the CEO has no clue about the science as demonstrated in every concall where the fat bastard lying CEO had to have Harry explain what was going on. The funniest thing about the call is where the CEO is asking his paid consultant to explain to him what the results meant. David Konman Koos is a dumb KLOWN. The only thing he knows how to do is how to use the company as his personal ATM,
BTW, the CEO of oncofakeapharma pleaded guilty. Remember, this is the guy that Koos opted to do business with. I said at the time onph was dirty and we know now it as a fraudulent company run by another fraud. Corrupt birds of a feather flock together. The SEC needs to investigate David Conman Koos.
https://www.justice.gov/usao-ma/pr/former-stockbroker-pleads-guilty-penny-stock-securities-fraud-scheme
What other reputable or sinky pinky bio companies use "Comfrimation" Studys ,lmao
Especially on old worthless patents/science , new bio science is light years ahead and beyond .
rgbp--->koosimodo got da dumpster-tan face peel, i see
$RGBP $1.55 Looking for a new HOD @ $1.60 Closing strong!
$RGBP Great Interview OUT! Regen BioPharma Inc. (OTC : RGBP) is a biotechnology company. Keynote speaker: David Koos, President / CEO & Harry M. Lander, Ph.D. Senior Scientific Consultant; Regen BioPharma Inc (OTC : RGBP) Link:
What ever they are being paid, it is a waste of money because they have no effect on the share price with all of the pumping they are doing. The stock is a big pile of crap and everyone knows it I have documented for years just how corrupt the con man is and how this company is a fraud.
How much are you compensated to promote this scam this time around?
Why won't you answer this simple question?
$RGBP "Upcoming milestones include new CRO confirmatory study results, animal studies, and an IND submission. The IND submission could lead to a Phase I clinical (human) trial in 18+ months." https://www.marketwatch.com/press-release/goldman-small-cap-research-publishes-new-research-report-on-regen-biopharma-inc-fe695ae1?mod=mw_quote_news_seemore $FSR $GOEV $GM $PHBI $BEGI $QS $F $TGGI $RDAR $AMC $GME $LCID
Should see a nice move to the 50day.
$RGBP
rgbp--->somebody scrape the barnacle off koosimodo's face please
Another Emerging Growth Train Wreck , not that BS again
The biggest problem is that with all of the blubbering form the fat bastard CEO and loser lander is that they need MONEY to further their research and they do not have that and never will.
Just listened to the CC. And it is hilarious that their test results did not provide the results they wanted. Their hypothesis was 100% wrong based on the data. It showed the opposite. What that tells you is that these clowns have no idea what they are doing as they went forward with testing thinking they knew what they had but they didn't. SO now they have to do more test to try and figure out if they can do anything with the Nerf.
The CEO also has no clue as to what he is doing. He's asking Harry how the company can pivot from small molecules to Car-T. He's the frickin CEO!
LOL
What a clown show.
$RGBP - Regen presentation archived from Emerging Growth Conference November 1, 2023
$RGBP $RGBPP
— Regen BioPharma Inc. (@TheRegenBio) November 3, 2023
Regen presentation archived from Emerging Growth Conference November 1, 2023https://t.co/idR3ZNPaWo
Yeah, I would guess so but I hoped that they'd PR about the conference and how it went.
$RGBP
The Emerging Growth presentation was yesterday. It can probably still be viewed if anybody missed it.
The company has had some great PRs over the past few weeks and I expect an update from the Emerging Growth Conference...
"We plan to use this time to discuss our most recent scientific results around our DuraCAR program as well as update our shareholders on our financial plan," says Dr. David Koos, CEO and Chairman of the Company.
$RGBP
$RGBP Oct. 25, 2023 9:30 AM ET -Regen BioPharma, Inc. PFD SER A NEW (RGBPP), RGBP
Autoimmunity to be Targeted
SAN DIEGO, Oct. 25, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) has previously discussed initiation of a series of experiments to validate its DuraCAR CAR T-cell therapeutic (https://www.prnewswire.com/news-releases/regen-biopharma-inc--begins-experiments-validating-its-proprietary-car-t-cell-therapy-301623585.html) while also identifying new, unexpected and potentially extremely useful findings in developing cell therapy treatments for autoimmune disorders https://www.prnewswire.com/news-releases/studies-on-regen-biopharma-incs-duracar-indicate-potential-suppression-of-autoimmunity-company-retains-contract-research-organization-to-conduct-additional-confirmatory-studies-301931365.html.
Very promising News...
"Being able to substantially elevate NR2F6 levels is truly an unexpected, but welcome finding. We now have a sound scientific basis to pursue designing T cells which can tamp down on the uncontrolled immune activation seen in multiple autoimmune disorders," says Dr. Harry Lander, Chief Scientific Consultant to the Company. "We recently filed a patent application around such T cells and we feel we have a head start on this in the scientific community, particularly around using nuclear receptors such as NR2F6."
$RGBP
Apparently not enough as the clown posse hasn't been able to pump the share price at all. Looks like some are going to get fired soon. Lol
How much are you being compensated to promote this stock?
You state publicly that you are compensated to promote stocks, yet refuse to answer how much this compensation is.
Why is that?
Looking forward to seeing an update from the conference within the next few days.
$RGBP
The clinical results data that RGBP now has in hand from confirming sources demonstrate that there is great potential in the company's approach.
The Company has now received the complete set of confirmatory data performed by a second contract research organization (CRO) which is independent of the CRO which performed the initial experiments. These data confirm that T cells which express the chimeric antigen receptor (CAR) construct targeting CD19 and expressing siRNA for NR2F6 had high expression levels of NR2F6 mRNA. NR2F6 is considered an immune checkpoint and thus increasing its activity is likely to lead to immune suppression.
Yes, the market is liking what RGBP has to say now and what is in development. Additionally, the Federal Reserve held even on interest rates again today which is good for the market in general. As we go forward the table is set here for pps appreciation.
$RGBP bullish move with today's presentation!
RGBP has a strong developing story in the emerging fields of advanced cancer treatments and for other important diseases.
Regen BioPharma, Inc. is a publicly traded biotechnology company (PINK: RGBP) and (PINK: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on mRNA and small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available athttp://www.regenbiopharmainc.com.
Followers
|
1050
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
118424
|
Created
|
09/03/14
|
Type
|
Free
|
Moderators Huggy Bear SmellMyFinger |
0.000x Ticker Symbol: RGBP
Barchart
All other Regen BioPharma News
https://www.regenbiopharmainc.com/company-news.html
Date | Outsanding Shares | Reason for Issue |
---|---|---|
12/31/21 | 4,564,002,832 | |
3/28/22 | 4,580,002,832 | Debt and Interest |
4/7/22 | 4,736,002,832 | Debt and Interest |
5/16/22 | 4,820,002,832 | Debt |
7/1/22 | 4,920,002,832 | Debt |
7/17/22 | 4,970,002,832 | Debt and Interest |
8/1/22 | 5,024,517,324 | Debt |
8/4/22 | 5,031,517,324 | EXPENSES |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |